WEBSITE BSE:543657 NSE: ACI Inc. Year: 2009 Industry: Chemicals My Bucket: Add Stock
Last updated: 15:59
No Notes Added Yet
1. Business Overview
Archean Chemical Industries Ltd. is a leading specialty marine chemical manufacturer in India, primarily focused on the production and export of Bromine and Industrial Salt. The company leverages its exclusive access to brine reserves in the Rann of Kutch, Gujarat, to extract these chemicals. Its core business model involves integrated manufacturing, producing high-purity Bromine for diverse applications (pharmaceuticals, agrochemicals, flame retardants, water treatment) and Industrial Salt, largely for the chlor-alkali industry and captive consumption. Archean also produces Potassium Sulphate (SOP), a specialty fertilizer. The company makes money by selling these industrial and specialty chemicals to customers across various industries globally.
2. Key Segments / Revenue Mix
Archean Chemical's revenue is primarily driven by:
Bromine: This is the largest revenue contributor, accounting for a significant majority of sales (historically over 70%).
Industrial Salt: The second major segment, contributing a substantial portion (typically 15-20%) to overall revenue.
Potassium Sulphate (SOP): A smaller but growing segment, contributing the remaining share.
While specific percentages fluctuate with market prices and sales volume, Bromine remains the dominant revenue driver.
3. Industry & Positioning
The marine chemical industry, particularly for bromine, is characterized by high entry barriers due to limited access to brine reserves, high capital expenditure, and complex manufacturing processes. Globally, the bromine market is largely oligopolistic. Archean Chemical holds a strong position as India's largest exporter of industrial salt and a significant producer of bromine globally. It is among the top few global bromine manufacturers and a key domestic producer, serving both Indian and international markets. Its strategic location and integrated operations provide a cost advantage over many peers.
4. Competitive Advantage (Moat)
Exclusive Resource Access: Archean possesses exclusive long-term rights to extract brine from 24,000 hectares in the Rann of Kutch, a geographically advantageous location for marine chemical production. This ensures a stable and cost-effective raw material supply.
Cost Leadership: Integrated manufacturing operations (using captive salt for bromine production), captive power generation, and proximity to ports contribute to a lower cost of production and logistics.
High Entry Barriers: The industry requires significant capital investment, specialized technical expertise, and long lead times for setting up operations, deterring new entrants.
Product Purity & Quality: The company's focus on high-purity products is critical for end-user industries like pharmaceuticals and electronics, fostering strong customer relationships.
Scale & Efficiency: Large-scale, efficient production facilities allow for competitive pricing and economies of scale.
5. Growth Drivers
Rising Demand for Bromine: Growth in end-user industries such as pharmaceuticals, agrochemicals, water treatment, specialty chemicals, and new applications like energy storage (e.g., flow batteries) will drive bromine demand.
Capacity Expansion: Planned expansions in both Bromine and SOP manufacturing capacities will allow Archean to cater to increasing demand and gain market share.
Global Market Penetration: Continued focus on expanding its export footprint across various geographies for both Bromine and Industrial Salt.
Specialty Fertilizer Growth: Increasing awareness and adoption of specialty fertilizers like SOP for high-value crops will boost demand.
Value-added Derivatives: Potential for backward integration into bromine derivatives, offering higher margins and product diversification.
6. Risks
Commodity Price Volatility: Prices of Bromine and Industrial Salt are subject to global supply-demand dynamics and can be volatile, impacting profitability.
Regulatory & Environmental Risks: Stricter environmental regulations on brine extraction, chemical manufacturing, or the use of certain bromine compounds (e.g., specific flame retardants) could affect operations and demand.
Logistics & Geopolitical Risks: As a significant exporter, the company is exposed to risks related to international trade policies, shipping costs, and geopolitical instability.
Competition: While oligopolistic, competition from other global bromine producers could impact market share and pricing.
Foreign Exchange Fluctuations: A substantial portion of revenue is from exports, making the company susceptible to adverse movements in foreign currency exchange rates.
Execution Risk: Delays or cost overruns in planned capacity expansion projects could impact future growth projections.
7. Management & Ownership
Archean Chemical Industries Ltd. is a promoter-driven company. The promoters have a deep understanding of the marine chemicals industry and have been instrumental in establishing and scaling the business. The company successfully completed its Initial Public Offering (IPO) in November 2022. The ownership structure includes the promoter group holding a significant stake, alongside institutional investors and public shareholders. The management team comprises experienced professionals with expertise in chemical operations, international trade, and finance.
8. Outlook
Archean Chemical is well-positioned in the specialty marine chemicals sector, leveraging its integrated operations and exclusive resource access. The demand outlook for its key products like Bromine remains positive, driven by growth in critical end-user industries globally. Planned capacity expansions and focus on export markets are expected to fuel future growth. However, the company faces inherent risks associated with commodity price volatility and potential regulatory changes. Successful execution of expansion plans and effective risk management will be crucial for sustained performance.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹6657 Cr.
Stock P/E 41.1
P/B 3.4
Current Price ₹539.3
Book Value ₹ 156.7
Face Value 2
52W High ₹727.8
Dividend Yield 0.46%
52W Low ₹ 483.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 413 | 284 | 213 | 240 | 242 | 346 | 292 | 233 | 255 | 301 |
| Other Income | 9 | 12 | 10 | 11 | 9 | 8 | 8 | 6 | 7 | 5 |
| Total Income | 422 | 296 | 222 | 251 | 251 | 353 | 301 | 240 | 262 | 306 |
| Total Expenditure | 267 | 197 | 141 | 166 | 162 | 257 | 214 | 171 | 200 | 257 |
| Operating Profit | 155 | 99 | 81 | 86 | 89 | 96 | 86 | 69 | 61 | 49 |
| Interest | 2 | 2 | 2 | 3 | 3 | 0 | 5 | 6 | 4 | 10 |
| Depreciation | 18 | 18 | 19 | 19 | 20 | 21 | 23 | 24 | 24 | 23 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -40 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 135 | 80 | 61 | 23 | 66 | 75 | 58 | 40 | 33 | 16 |
| Provision for Tax | 34 | 22 | 16 | 7 | 18 | 21 | 18 | 11 | 9 | 4 |
| Profit After Tax | 102 | 58 | 45 | 16 | 48 | 54 | 40 | 29 | 24 | 12 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | 1 |
| Profit After Adjustments | 102 | 58 | 45 | 16 | 48 | 54 | 40 | 29 | 24 | 13 |
| Adjusted Earnings Per Share | 8.2 | 4.7 | 3.6 | 1.3 | 3.9 | 4.3 | 3.3 | 2.4 | 1.9 | 1.1 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 341 | 288 | 439 | 566 | 608 | 1130 | 1441 | 1330 | 1041 | 1081 |
| Other Income | 1 | 4 | 6 | 7 | 9 | 12 | 43 | 43 | 37 | 26 |
| Total Income | 342 | 292 | 445 | 573 | 617 | 1143 | 1484 | 1373 | 1078 | 1109 |
| Total Expenditure | 235 | 218 | 356 | 493 | 460 | 663 | 807 | 867 | 727 | 842 |
| Operating Profit | 107 | 74 | 89 | 80 | 157 | 480 | 677 | 506 | 351 | 265 |
| Interest | 106 | 106 | 102 | 118 | 122 | 162 | 97 | 8 | 8 | 25 |
| Depreciation | 72 | 81 | 73 | 49 | 52 | 67 | 69 | 70 | 79 | 94 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 114 | 0 | 0 | 0 | 0 | -40 | 0 |
| Profit Before Tax | -72 | -113 | -85 | 27 | -17 | 251 | 512 | 427 | 224 | 147 |
| Provision for Tax | 14 | -40 | -6 | -13 | 20 | 63 | 129 | 108 | 62 | 42 |
| Profit After Tax | -87 | -74 | -79 | 40 | -36 | 188 | 383 | 319 | 162 | 105 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Profit After Adjustments | -87 | -74 | -79 | 40 | -36 | 188 | 383 | 319 | 162 | 106 |
| Adjusted Earnings Per Share | -17.3 | -14.7 | -15.8 | 4.1 | -3.8 | 19.5 | 31.1 | 25.8 | 13.1 | 8.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -22% | -3% | 13% | 0% |
| Operating Profit CAGR | -31% | -10% | 34% | 0% |
| PAT CAGR | -49% | -5% | 32% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -12% | 0% | NA% | NA% |
| ROE Average | 9% | 25% | 13% | -92% |
| ROCE Average | 12% | 29% | 28% | 18% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 114 | 40 | -28 | 42 | 6 | 262 | 1431 | 1702 | 1864 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 589 | 817 | 792 | 741 | 848 | 843 | 1 | 59 | 152 |
| Other Non-Current Liabilities | 81 | 33 | 5 | 243 | 244 | 251 | 151 | 283 | 176 |
| Total Current Liabilities | 553 | 347 | 410 | 143 | 254 | 176 | 193 | 135 | 359 |
| Total Liabilities | 1337 | 1237 | 1178 | 1170 | 1352 | 1531 | 1776 | 2179 | 2551 |
| Fixed Assets | 1013 | 994 | 940 | 936 | 916 | 1086 | 1110 | 1160 | 1378 |
| Other Non-Current Assets | 73 | 17 | 77 | 45 | 174 | 46 | 68 | 293 | 320 |
| Total Current Assets | 251 | 226 | 161 | 189 | 262 | 399 | 598 | 726 | 853 |
| Total Assets | 1337 | 1237 | 1178 | 1170 | 1352 | 1531 | 1776 | 2179 | 2551 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 70 | 69 | 61 | 12 | 47 | 32 | 12 | 6 | 46 |
| Cash Flow from Operating Activities | 271 | -77 | 39 | 316 | 148 | 315 | 496 | 379 | 176 |
| Cash Flow from Investing Activities | -55 | 4 | -6 | -25 | -197 | -110 | -290 | -307 | -246 |
| Cash Flow from Financing Activities | -218 | 65 | -87 | -256 | 26 | -224 | -212 | -33 | 65 |
| Net Cash Inflow / Outflow | -1 | -8 | -54 | 35 | -23 | -19 | -6 | 40 | -5 |
| Closing Cash & Cash Equivalent | 69 | 61 | 13 | 47 | 24 | 12 | 6 | 45 | 41 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -17.33 | -14.72 | -15.84 | 4.15 | -3.76 | 19.55 | 31.09 | 25.85 | 13.14 |
| CEPS(Rs) | -2.85 | 1.55 | -1.29 | 9.27 | 1.61 | 26.48 | 36.67 | 31.55 | 19.57 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 2.5 | 3 | 3 |
| Book NAV/Share(Rs) | 22.81 | 8.09 | -5.63 | 4.4 | 0.62 | 27.23 | 115.68 | 137.7 | 150.83 |
| Core EBITDA Margin(%) | 30.24 | 23.46 | 18.74 | 12.85 | 24.33 | 41.33 | 44 | 34.78 | 30.18 |
| EBIT Margin(%) | 9.81 | -2.54 | 3.64 | 25.64 | 17.27 | 36.51 | 42.24 | 32.75 | 22.27 |
| Pre Tax Margin(%) | -20.73 | -38.22 | -19.34 | 4.84 | -2.75 | 22.2 | 35.51 | 32.12 | 21.5 |
| PAT Margin (%) | -24.89 | -24.85 | -17.93 | 7.07 | -5.96 | 16.65 | 26.55 | 23.98 | 15.58 |
| Cash Profit Margin (%) | -4.09 | 2.61 | -1.46 | 15.79 | 2.55 | 22.56 | 31.31 | 29.27 | 23.2 |
| ROA(%) | -6.48 | -5.72 | -6.56 | 3.4 | -2.87 | 13.06 | 23.13 | 16.13 | 6.86 |
| ROE(%) | -75.95 | -95.29 | -1287.76 | 562.49 | -149.92 | 140.32 | 45.39 | 20.43 | 9.11 |
| ROCE(%) | 3.1 | -0.71 | 1.65 | 16.7 | 12.66 | 41.89 | 47.56 | 27.11 | 12.19 |
| Receivable days | 44.23 | 42.37 | 21.92 | 30.17 | 33.45 | 31.87 | 34.28 | 37.61 | 56.27 |
| Inventory Days | 118.68 | 147.92 | 98.94 | 56.57 | 48.48 | 35.45 | 36.54 | 40.48 | 51.79 |
| Payable days | -2222.99 | 1245.36 | 934.63 | 467.53 | 0 | 1296.82 | 0 | 406.67 | -4796.95 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 20.93 | 25.92 | 39.24 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 5.63 | 4.87 | 3.42 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0.38 | 0.45 | 0.58 |
| EV/Net Sales(x) | 2.73 | 3.2 | 2.2 | 1.28 | 1.4 | 0.71 | 5.55 | 6.23 | 6.23 |
| EV/Core EBITDA(x) | 8.73 | 12.47 | 10.87 | 9.06 | 5.43 | 1.68 | 11.81 | 16.37 | 18.46 |
| Net Sales Growth(%) | 0 | -15.53 | 52.56 | 28.87 | 7.54 | 85.88 | 27.48 | -7.7 | -21.73 |
| EBIT Growth(%) | 0 | -122.02 | 314.12 | 800.71 | -27.56 | 292.84 | 47.48 | -28.42 | -46.78 |
| PAT Growth(%) | 0 | 15.02 | -7.59 | 150.46 | -190.65 | 619.41 | 103.26 | -16.62 | -49.17 |
| EPS Growth(%) | 0 | 15.02 | -7.59 | 126.19 | -190.65 | 619.69 | 59.04 | -16.85 | -49.18 |
| Debt/Equity(x) | 8.67 | 24.02 | -34.39 | 17.8 | 143.6 | 3.22 | 0.02 | 0.04 | 0.1 |
| Current Ratio(x) | 0.45 | 0.65 | 0.39 | 1.32 | 1.03 | 2.27 | 3.09 | 5.38 | 2.38 |
| Quick Ratio(x) | 0.25 | 0.29 | 0.12 | 0.88 | 0.64 | 1.58 | 2.22 | 4.44 | 1.91 |
| Interest Cover(x) | 0.32 | -0.07 | 0.16 | 1.23 | 0.86 | 2.55 | 6.28 | 51.49 | 28.61 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.03 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 53.45 | 53.45 | 53.45 | 53.45 | 53.44 | 53.44 | 53.44 | 53.44 | 53.43 | 53.43 |
| FII | 4.15 | 5.86 | 9.53 | 10.17 | 10.65 | 10.94 | 11.05 | 11.15 | 11.08 | 11.09 |
| DII | 28.69 | 27.14 | 21.04 | 21.82 | 22.68 | 23 | 24.68 | 25.52 | 25.25 | 25.71 |
| Public | 13.71 | 13.54 | 15.97 | 14.56 | 13.24 | 12.62 | 10.83 | 9.89 | 10.25 | 9.78 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 |
| FII | 0.51 | 0.72 | 1.18 | 1.25 | 1.31 | 1.35 | 1.36 | 1.38 | 1.37 | 1.37 |
| DII | 3.54 | 3.35 | 2.6 | 2.69 | 2.8 | 2.84 | 3.05 | 3.15 | 3.12 | 3.17 |
| Public | 1.69 | 1.67 | 1.97 | 1.8 | 1.63 | 1.56 | 1.34 | 1.22 | 1.27 | 1.21 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12.34 | 12.34 | 12.34 | 12.34 | 12.34 | 12.34 | 12.34 | 12.34 | 12.35 | 12.35 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.